Navigation Links
Clinical Validation Study Confirms PromarkerD Can Predict Diabetic Kidney Disease Better than any Current Measure

Presented at American Diabetes Association: Abstract #2017-LB-7091-Diabetes

  • PromarkerD test predicted 86% of previously disease-free patients who went on to develop chronic kidney disease within four years
  • Study is the largest prospective clinical study on diabetic kidney disease in the community and evaluated 792 patients over a four year period
  • Results presented at the American Diabetes Association's 77th Annual Scientific Sessions in the Late-breaking Abstracts section of the conference, 9-13th June 2017, San Diego
  • If unchecked, the International Diabetes Federation predicts the 'at risk' population will be 642 million by 2040, and the number of diabetics with chronic kidney disease will rise by 76 million to 214 million.
  • PromarkerD has the potential to save healthcare systems around the world billions of dollars in costs associated with treating diabetic kidney disease

San Diego, June 10th - Proteomics International Laboratories Ltd (ASX: PIQ) (PILL) announced today results from its validation clinical study showing that the PromarkerD blood test can predict the onset of diabetic kidney disease better than any current measure. These findings will be presented by Professor Tim Davis, from The University of Western Australia Medical School, at the American Diabetes Association's 77th Annual Scientific Sessions (ADA), 9-13th June, in San Diego, California.

The study, undertaken as a joint collaboration between Proteomics International and The University of Western Australia, is the largest prospective clinical study on diabetic kidney disease in the community and evaluated the clinical utility of PromarkerD with 792 patients. In March, Frost & Sullivan identified PromarkerD as the world's leading test for diabetic kidney disease, and the new results confirm PromarkerD predicts rapid decline in kidney function in type 2 diabetes, across clinically significant definitions of disease, independently of recognized clinical risk factors.

According to the International Diabetes Federation, 415 million adults had diabetes in 2015. The US Center for Disease Control states that one in three adult diabetics have chronic kidney disease, or 138 million people today. Once detected, chronic kidney disease can be treated through medication and lifestyle changes to slow down the disease progression, and to prevent or delay the onset of kidney failure. The International Diabetes Federation further predicts the number of diabetics will rise to 642 million by 2040, which, if unchecked, will increase the number of adults with chronic kidney disease by 76 million to 214 million. The current cost of dialysis is estimated at $100,000 per person per year. The validation study (assessing the performance of the prediction model in an independent population) confirms results from the original development study, also completed in collaboration with Professor Davis. Initial findings on the diagnostic performance of PromarkerD were published in the European Journal of Proteomics in March 2017.

In the four-year prospective study, the three protein marker (biomarker) blood test (PromarkerD) predicted 86% of previously disease-free patients who went on to develop chronic kidney disease (Sensitivity 86%, Specificity 78%, AUC 0.88). In comparison to the development study the results from the larger validation study showed slightly lower levels of predictive ability (development 95%), however, achieved a 10% improvement in levels of false positives.

Professor Davis concluded, “The data support the use of the protein biomarker panel in conjunction with eGFR (estimated glomerular filtration rate) in patients with type 2 diabetes to monitor and predict their decline in kidney function.”

“This large clinical study validates the important role of the PromarkerD test to effectively monitor patients with diabetes,” said Dr Richard Lipscombe, Managing Director of Proteomics International. “Although patients may appear to be adequately controlled for the complications of diabetes, current tests do not reveal early symptoms of kidney disease, which can result in the need for dialysis or kidney transplant.”

The annual ADA Scientific Sessions are the world’s largest and most prominent meeting of diabetes experts, attracting more than 13,000 delegates. The results will be reported in the Late-breaking Abstracts section of the conference, titled, “Novel Circulating Biomarkers Predicting Rapidly Declining Renal Function in Type 2 Diabetes: The Fremantle Diabetes Study”. PILL’s head of business development Chuck Morrison will also attend the event.

PromarkerD - a predictive diagnostic test for diabetic kidney disease ( PromarkerD is a breakthrough blood test that uses a protein ‘fingerprint’ to measure kidney disease in patients with diabetes. This ground-breaking test can both diagnose and predict disease.

A published study in a peer-reviewed journal has shown that for diabetic patients already suffering from chronic kidney disease PromarkerD can diagnose the presence of disease that was missed by the current gold standard tests (known as the ACR and eGFR tests).

Critically, PromarkerD can also predict the onset of disease before clinical symptoms appear. In the current study 792 patients were followed in dual, four-year longitudinal clinical studies. PromarkerD correctly predicted 86% of the previously kidney disease-free diabetic patients who went on to develop chronic kidney disease.

Links and more information:
The Frost & Sullivan report titled “Biomarkers Enabling Diabetes and Obesity Management” is available via PILL’s website (


Watch HOW IT WORKS video here

The Fremantle Diabetes Study (FDS)
The Fremantle diabetes Study is a longitudinal observational study of a community-based, urban population in Fremantle, Western Australia. The study, which commenced in 1993 with a more recent phase II in 2008, contains over 3,000 recruits, and is headed by Professor Tim Davis of Fremantle Hospital and the Medical School at The University of Western Australia.

The strengths of the FDS are the inclusive and representative nature of the cohorts, the range and detail of data collection and linkage to well-established morbidity and mortality databases. The design and implementation of the FDS means that specific questions regarding the natural history of diabetes, its impact on the individual and its costs can be addressed with relative rigour.

The University of Western Australia
Ranked in the world’s top 100 universities, The University of Western Australia (UWA) is Western Australia’s first university and has an international reputation for excellence in education, research and community engagement. The University is located alongside the Swan River, five kilometres from the heart of Perth city. UWA’s cutting-edge research attracts high levels of competitive research funding and researchers who are global leaders in their field.

Proteomics International Laboratories (PILL) (
Proteomics International is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company focused on proteomics – the industrial scale study of the structure and function of proteins. PILL is recognised as a global leader in the field of proteomics. It received the world’s first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities located on the QEII Medical Campus in Perth, Western Australia. The Company’s business model uses its proprietary technology platform across three integrated areas of diagnostics,

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related biology technology :

1. Myonexus Therapeutics, Inc. Launches to Develop Pioneering, Clinical-Stage Gene Therapies Targeting Limb-Girdle Muscular Dystrophies
2. Bioclinica Introduces Pharmaceutical Industry’s First End-to-End Clinical Financial Lifecycle Platform
3. JDP Initiates Pivotal Phase 3 Clinical Trial of JDP-205 for Acute Urticaria
4. myClin And Clinical Works Announce Appointment Of VP Of Clinical Operations Kathy Goin
5. Clinical Supplies Management Names Two New Executives
6. Catalent Biologics Announces Collaboration with Therachon, Switzerland, to Advance Clinical Development of Innovative Protein Therapy for Achondroplasia
7. The Future of Clinical Research: Packaged in an App
8. Colpitts Clinical Continues to Provide Global Services to More Than 70 Countries
9. myClin Launches Clinical Works, A ClinOps And Creative Consultancy For Clinical Research
10. Industry leaders join Renova Therapeutics to lead preclinical programs into clinical development
11. EyeCRO and MPI Research Partner to Develop New Preclinical Models of Ophthalmic Disease
Post Your Comments:
(Date:7/19/2019)... , ... July 18, 2019 , ... ... announced their investment to enlarge their current piezo motion facilities in Lederhose, Germany, ... 3 floors for multilayer piezo ceramic assembly production in addition to general office ...
(Date:7/17/2019)... ... July 16, 2019 , ... ... a recent report from Kalorama Information. Abbott, Roche and Siemens Healthineers and Response ... Information’s latest report, Worldwide Market for Point-of-Care (POC) Diagnostics . , Quidel ...
(Date:7/2/2019)... ... 02, 2019 , ... Leading Regenerative Veterinary Medicine company, VetStem Biopharma , ... The film focuses on regenerative veterinary medicine as a means of improving the ... included in the Brentwood and Pacific Palisades International Film Festival in Los Angeles, ...
(Date:6/12/2019)... ... June 12, 2019 , ... ... testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries, is ... signed. The agreement will grant exclusive rights for Zillion to represent LDA in ...
Breaking Biology Technology:
(Date:7/26/2019)... ... 25, 2019 , ... Lemnis Technologies, the technology company behind ... a new generation eye tracker with hassle-free calibration. The headsets will be demonstrated ... - August 1). SIGGRAPH attendees will be able to try Verifocal™ headsets in ...
(Date:7/23/2019)... ... July 22, 2019 , ... Personalized Stem Cells, Inc (“PSC”), a human ... for use of a person’s own adipose-derived stem cells to treat their osteoarthritis. The ... of osteoarthritis in the knee. , This is the first of several ...
(Date:7/19/2019)... POWAY, Calif. (PRWEB) , ... July 18, 2019 , ... ... with clinical, regulatory and manufacturing experience. As a result of a two-year ... to commercialize the Calidi oncolytic virus platform in veterinary medicine. VetStem should be ...
Breaking Biology News(10 mins):